NHS National Framework for Transition Products (Nintedanib and Dalbavancin)

Buyer: NHS England

Deadline

Not available — this notice may describe a possible future opportunity.

Region

Not specified

Value

£14,758,000

Type

Award,contract

SME fit

—

Duration

—

Description

Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Awarded to

ZENTIVA PHARMA UK LIMITED £14,758,000 DR REDDY'S LABORATORIES (UK) LIMITED £14,758,000 ACCORD-UK LTD £14,758,000 CELIX PHARMA LTD £14,758,000 Baxter Healthcare Ltd £14,758,000 GLENMARK PHARMACEUTICALS EUROPE LIMITED £14,758,000 Wockhardt UK Limited £14,758,000

Quick actions

View original notice

Key details

CPV category: —
Procurement method: Open procedure
Published: 25 Feb 2026 13:10
VCSE suitable: —

Reference

OCID: ocds-h6vhtk-05d361
Notice ID: C397096
In our database since: 18 Aug 2026